Palvella Therapeutics Inc.

NASDAQ: PVLA
Share price (12/16/25): $96.81
Market cap (12/16/25): $1.146 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

ended 12/31/24 FY 2024

ended 09/30/24 Q3

Prospectuses and Registrations Filter

Registration of securities for employees

Prospectus supplement

Initial registration of new securities – amended

Initial registration of new securities

Business combination disclosure

Ownership Filter

Biotechnology Value Fund L P

Suvretta Capital Management, LLC

Samsara BioCapital, L.P.

News Filter

Achieved Statistical Significance on Multiple Pre-Specified Clinician-Reported and Patient-Reported Efficacy Endpoints, Including Dynamic Change Endpoints and Static Severity Endpoints

Reports Third Quarter 2025 Financial Results and Provides Corporate Update

DSAP Is a Premalignant, Progressive Disease Characterized by Numerous Expanding Lesions Which Significantly Impact Quality-Of-Life; No FDA-approved Therapies Exist for the Estimated More Than 50,000 Diagnosed U.S. Patients

Announces Expansion of QTORIN™ Rapamycin’s Development Into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease With No FDA-approved Therapies

Investor Presentation

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Other Filter

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

SEC STAFF LETTER